{"id":904022,"date":"2025-11-03T08:30:29","date_gmt":"2025-11-03T13:30:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/"},"modified":"2025-11-03T08:30:29","modified_gmt":"2025-11-03T13:30:29","slug":"kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/","title":{"rendered":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5XE7z7sAlOVjUtczB4QMwHa2HMiUBo2JlfLnUnirHMtr0Y-68HrB_tYmx3u17z0mlUgfYyQhtEP5y0VVmcRv2RuI9oWx3Q3J7c1vR5zBTrA=\" rel=\"nofollow\" target=\"_blank\">Kymera Therapeutics, Inc.<\/a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0<\/p>\n<ul type=\"disc\">\n<li>Guggenheim 2<sup>nd<\/sup> Annual Healthcare Innovation Conference in Boston, MA on November 10 at 9:00 a.m. ET;<\/li>\n<li>UBS 2025 Global Healthcare Conference in Palm Beach, FL on November 10 at 11:45 a.m. ET;<\/li>\n<li>Stifel 2025 Healthcare Conference in New York, NY on November 11 at 1:20 p.m. ET;<\/li>\n<li>TD Cowen Virtual Immunology &amp; Inflammation Summit on November 13 at 10:30 a.m. ET; and<\/li>\n<li>Jefferies Global Healthcare Conference in London, UK on November 19 at 11:00 a.m. GMT.<\/li>\n<\/ul>\n<p>Live webcasts of the presentations will be available under \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7emOUi3v6dq9CbEOgKdVkE01ML3o99F72IpwPQsPRhntShX0OC-aMmZOW2SeL0UtQDvKKeeC9KQx0ULl53HNc_kx_dVDVeLITat8F2Vv5Va0aJHhi5gnpPCOITHlp0L2\" rel=\"nofollow\" target=\"_blank\">News and Events<\/a>\u201d in the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0pdy6ToUxsAKcU1-mYv07z9TTmD3VuQS32DXdJFJxRGsIxkNrkCO5tNQv959vcLQyekG0mUU4El6192jmzjYUHQxlRedxsEDnnSh70y8Ems=\" rel=\"nofollow\" target=\"_blank\">www.kymeratx.com<\/a>. Replays of the webcasts will be archived and available following the events.\u00a0<\/p>\n<p>\n        <strong>About Kymera Therapeutics<\/strong>\u00a0<br \/>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients\u2019 lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston\u2019s top workplaces for the past several years. For more information about our science, pipeline and people, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0pdy6ToUxsAKcU1-mYv076uZqJgfT3Xpd4Dt02TYYMyIEKJH4a0moIXQZlGDxN-6H2QRca4xzE7AOPIl6omW-b_Y8DsvqdHD2o73eEUUYw0=\" rel=\"nofollow\" target=\"_blank\">www.kymeratx.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KOdfY1zaLGezyVQlVSBoLRa7kDviS-nu5svNweEJKsT0RfOsY3-RTSRhCVnwmhbXTvtsZu0pQCSDfPGqF4kh2w==\" rel=\"nofollow\" target=\"_blank\">X<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nsT8Erzm6K6fSFFiS1UG4UTj0YC77FMeY9uosInTr_Z4p4h-svuX7DcHMu2HUzSnJZNbakOuO6XXhzjkYffrwsXpRo3_hNmNoo1ayc1e0FK2rJJCvoTdXItyWL3LFDLR\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.\u00a0<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong>\u00a0<br \/>Justine Koenigsberg<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IueOrvwTBLKL7V3mttRIxopq3SamjAyBkmXRYX4gIjuKxAyit1DE-7na1J3sfQB-B5O2dawHugm-rWyMaFPe-cOw7eBoUYouvD9te8uBFAc=\" rel=\"nofollow\" target=\"_blank\">investors@kymeratx.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m1YC7w7Zc2Ml51RUUQDU15MUrHR0tk3HmqCDn2h2MecGOZw_XeHzkjxTZSOCsxi-lGDWMx1jGk16-RybL79SWxBlludFkRChQBnIYAUivz0=\" rel=\"nofollow\" target=\"_blank\">media@kymeratx.com<\/a><br \/>857-285-5300\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDM2Mjc3MjMtZTUwMi00Y2VmLWFhZTQtOTliMGNiYmQ0YTRjLTEyMTIzODUtMjAyNS0xMS0wMy1lbg==\/tiny\/Kymera-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0 Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on November 10 at 9:00 a.m. ET; UBS 2025 Global Healthcare Conference in Palm Beach, FL on November 10 at 11:45 a.m. ET; Stifel 2025 Healthcare Conference in New York, NY on November 11 at 1:20 p.m. ET; TD Cowen Virtual Immunology &amp; Inflammation Summit on November 13 at 10:30 a.m. ET; and Jefferies Global Healthcare Conference in London, UK on November 19 at 11:00 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kymera Therapeutics to Participate in Upcoming November Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymera Therapeutics to Participate in Upcoming November Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics to Participate in Upcoming November Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0 Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on November 10 at 9:00 a.m. ET; UBS 2025 Global Healthcare Conference in Palm Beach, FL on November 10 at 11:45 a.m. ET; Stifel 2025 Healthcare Conference in New York, NY on November 11 at 1:20 p.m. ET; TD Cowen Virtual Immunology &amp; Inflammation Summit on November 13 at 10:30 a.m. ET; and Jefferies Global Healthcare Conference in London, UK on November 19 at 11:00 &hellip; Continue reading &quot;Kymera Therapeutics to Participate in Upcoming November Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:30:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics to Participate in Upcoming November Investor Conferences\",\"datePublished\":\"2025-11-03T13:30:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/\",\"name\":\"Kymera Therapeutics to Participate in Upcoming November Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=\",\"datePublished\":\"2025-11-03T13:30:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics to Participate in Upcoming November Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences - Market Newsdesk","og_description":"WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:\u00a0 Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on November 10 at 9:00 a.m. ET; UBS 2025 Global Healthcare Conference in Palm Beach, FL on November 10 at 11:45 a.m. ET; Stifel 2025 Healthcare Conference in New York, NY on November 11 at 1:20 p.m. ET; TD Cowen Virtual Immunology &amp; Inflammation Summit on November 13 at 10:30 a.m. ET; and Jefferies Global Healthcare Conference in London, UK on November 19 at 11:00 &hellip; Continue reading \"Kymera Therapeutics to Participate in Upcoming November Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:30:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences","datePublished":"2025-11-03T13:30:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/","name":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=","datePublished":"2025-11-03T13:30:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjkyMCM3MjM3MzI2IzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-participate-in-upcoming-november-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics to Participate in Upcoming November Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}